Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

The burden of childhood cancers in the South Asian Association for Regional Cooperation (SAARC) region: A GLOBOCAN 2022 analysis.

Tara Pattilachan Menon, Jazlyn Selvasingh, Taral Kumar Jella et al. Jun 01, 2026 pp. 10022-10022 10.1200/jco.2026.44.16_suppl.10022

10022 Background: Countries of the South Asian Association for Regional Cooperation (SAARC) are home to approximately 600...

Metastatic renal cell carcinoma treated with pembrolizumab–lenvatinib versus nivolumab–cabozantinib: A real-world analysis.

Maksim Isachanka, Okan Cetin, Harmanjit Kaur et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16519

e16519 Background: Pembrolizumab plus lenvatinib (P-L) and nivolumab plus cabozantinib (N-C) are approved first-line optio...

Initial results of a phase 1 dose exploration and expansion study of xaluritamig plus abiraterone acetate (AA) in patients (pts) with mCRPC.

Christopher Joseph Sumey, Stefanie Fischer, Jose Luis Perez-Gracia et al. Jun 01, 2026 pp. 5070-5070 10.1200/jco.2026.44.16_suppl.5070

5070 Background: Xaluritamig (xalu) is a STEAP1 x CD3 T-cell engager, that has shown potent, durable monotherapy activity...

Quantifying the impact of protocol design on enrollment and dropout rates in breast cancer clinical trials.

Evon Okidi, Sheila Diamond, Eric Yang et al. Jun 01, 2026 pp. 11027-11027 10.1200/jco.2026.44.16_suppl.11027

11027 Background: Clinical trial enrollment can sometimes fail due to protocol design being overly complex, including proc...

Efficacy analysis of high-dose-rate brachytherapy combined with total neoadjuvant therapy versus total neoadjuvant therapy alone.

Huangang Jiang, Chenping Fu, Lei Yang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15663

e15663 Background: Colorectal cancer is the third most common tumors and the second leading cause of cancer-related deaths...

Regional trends in testicular cancer burden among adolescents and young adults (15–39 years), 1990–2023: A Global Burden of Disease analysis.

Vanshika Singh, Jay Tewari, Priyam Nayak et al. Jun 01, 2026 pp. 5030-5030 10.1200/jco.2026.44.16_suppl.5030

5030 Background: Testicular cancer is the most common solid malignancy in adolescent and young adult (AYA) males. Contempo...

Real-world outcomes of axicabtagene ciloleucel in older versus younger adults with diffuse large B-cell lymphoma.

Adithya Nagendran, Anushree Venkatesh Murthy, Logesh Durairaj et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19102

e19102 Background: Axicabtagene ciloleucel (axi-cel) has substantially improved outcomes for patients with relapsed or ref...

Greening a chemotherapy day ward.

Alannah Kelly, Amy Richards, Ciarán Kennedy et al. Jun 01, 2026 pp. 1567-1567 10.1200/jco.2026.44.16_suppl.1567

1567 Background: Cancer care is climate toxic and contributes to the triple planetary crisis which threatens human health...

Post-treatment cervical cancer surveillance cytology and recurrence outcomes in a large integrated healthcare system.

Maliha Khan, Belia Ordonez Roybal, Nhi Nguyen et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17507

e17507 Background: Post-treatment cervical cancer surveillance strategies are used to facilitate timely detection of recur...

Tumor-specific drivers of PD-1/PD-L1 inhibitor brand preference in NSCLC, melanoma, and renal cell carcinoma: A U.S. oncologist perspective.

Olivia Parry, Kimberly Peihsi Ku, Sarah Hendry Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23229

e23229 Background: Multiple PD-1/PD-L1 inhibitors are approved across solid tumors with overlapping indications. Despite c...

Initial safety and efficacy of A2B694, a logic-gated mesothelin (MSLN)–targeted Tmod chimeric antigen receptor T-cell (CAR T) therapy in patients with advanced solid tumors with HLA-A*02 loss of heterozygosity (LOH).

Julian R. Molina, Jeffrey Ward, Joel R. Hecht et al. Jun 01, 2026 pp. 8579-8579 10.1200/jco.2026.44.16_suppl.8579

8579 Background: LOH may provide a means to target tumor versus normal cells, to augment the efficacy and safety of MSLN-t...

Association of NAB2–STAT6 distal fusion with risk level of metastatic disease and thoracic primary site.

Keerthana Sureshkumar, Mason Thornton, Eric Jung et al. Jun 01, 2026 pp. 11519-11519 10.1200/jco.2026.44.16_suppl.11519

11519 Background: Solitary fibrous tumors (SFTs) are defined by the NAB2–STAT6 gene fusion, but the clinical significance...

Clinical outcomes and safety of central nervous system tumor patients in phase 1 trials: A single-institution experience.

Fatma Nihan Akkoc Mustafayev, Zouina Sarfraz, Xiaoou Pan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14047

e14047 Background: Central nervous system (CNS) tumors present unique therapeutic challenges due to limited drug penetrati...

Phase I study of [ <sup>225</sup> Ac]Ac-ETN029, a DLL3-targeted radioligand therapy, in patients with advanced DLL3-expressing solid tumors.

Cristiano Ferrario, Yusuf Menda, Shadi Abdar Esfahani et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps3174

TPS3174 Background: Delta-like ligand 3 (DLL3) is an atypical Notch ligand that is highly expressed in small cell lung can...

Gender distribution of international cancer research funding.

Elise Garton, Constance Burgod, Tosca Le et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e21018

e21018 Background: The Lancet Commission on women, power, and cancer recommends th...

Economic factors and screening practices in global lung cancer staging disparities: A systematic review.

Lanwei Guo, Chenxin Zhu, Le Wang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22500

e22500 Background: To assess the global distribution of lung cancer staging at diagnosis and explore the impact of...

AhR as a coupler of tryptophan metabolism to immune checkpoint regulation in breast cancer.

Yanming Wu, Yufan Zhou, Kai Wang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12579

e12579 Background: Tryptophan (Trp) is an essential amino acid metabolized through the kynurenine, serotonin, and indole p...

Long-term outcomes of SINTART 1 and SINTART 2: Two phase II trials of multimodal treatments in patients with locally advanced sinonasal carcinomas.

Arianna Ottini, Stefano Cavalieri, Carlo Resteghini et al. Jun 01, 2026 pp. 6120-6120 10.1200/jco.2026.44.16_suppl.6120

6120 Background: Sinonasal carcinomas (SNCs) are rare malignancies with poor prognosis. Multimodal treatments including in...

An artificial intelligence–based framework for longitudinal risk prediction in patients with cirrhosis through trajectory modeling: A multi-center prospective study in time-series cohorts.

Xiaopeng Tian, Hailong Li, Song-Bin Guo et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16011

e16011 Background: Surveillance for hepatocellular carcinoma (HCC) in adults with cirrhosis relies on fixed-interval AFP t...

Understanding patient engagement with an oncology chatbot: Thematic and sentiment analysis of medical adherence.

Weilu Song, Chelsea Saia, Jocelyn Wainwright et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13705

e13705 Background: Oral oncology treatment is an effective option, but faces challenges of suboptimal adherence. Penny, an...

Intraductal carcinoma of the prostate as a predictor of efficacy of olaparib combined with novel hormone therapy in metastatic castration-resistant prostate cancer.

Qiyu Zhu, Ling Wang, Junru Chen et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17063

e17063 Background: Intraductal carcinoma of the prostate (IDC-P) is a clinicopathological entity of prostate cancer charac...

Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor–positive and human epidermal growth factor receptor 2–negative (HR+/HER2−) advanced breast cancer (ABC) from the high-altitude versus low-altitude regions: A multi-center retrospective study.

Yujing Tan, Yinyin Ye, Ying Fan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13033

e13033 Background: Hypoxia in the high-altitude regions may alter the pharmacokinetic properties of anti-tumor drugs, incl...

Long-term mortality trends of cervical cancer among younger and middle-aged women in the United States.

Vishan Das, Dua Azim, Shehdev Meghwar et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17504

e17504 Background: Despite increasing human papillomavirus (HPV) immunization rates, the incidence of cervical cancer has...

Asciminib in newly diagnosed Philadelphia chromosom–positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP): A retrospective chart review study in the US.

Ehab L. Atallah, Islam Sadek, Andrea Damon et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23076

e23076 Background: Asciminib, the first BCR:ABL1 inhibitor specifically targeting the ABL myristoyl pocket, received US FD...

Recognition and management patterns of cachexia in patients with pancreatic adenocarcinoma in a safety net hospital.

Neeraj Ramakrishnan, Kailyn Kim, Hope Cassano et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24079

e24079 Background: Cachexia is a metabolic syndrome marked by disrupted protein and energy balance, affecting up to 80% of...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page